Related Experiment Video
Updated: Jun 27, 2025

Visualization, Quantification, and Mapping of Immune Cell Populations in the Tumor Microenvironment
Published on: March 25, 2020
A Pathologically Friendly Strategy for Determining the Organ-specific Spatial Tumor Microenvironment Topology in Lung
Xuqi Sun1, Xiao Teng2, Chuan Liu1
1Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, China.
Abstract:
Heterogeneous organ-specific responses to immunotherapy exist in lung cancer. Dissecting tumor microenvironment (TME) can provide new insights into the mechanisms of divergent responses, the process of which remains poor, partly due to the challenges associated with single-cell profiling using formalin-fixed paraffin-embedded (FFPE) materials. In this study, single-cell nuclei RNA sequencing and imaging mass cytometry (IMC) are used to dissect organ-specific cellular and spatial TME based on FFPE samples from paired primary lung adenocarcinoma (LUAD) and metastases. Single-cell analyses of 84 294 cells from sequencing and 250 600 cells from IMC reveal divergent organ-specific immune niches. For sites of LUAD responding well to immunotherapy, including primary LUAD and adrenal gland metastases, a significant enrichment of B, plasma, and T cells is detected. Spatially resolved maps reveal cellular neighborhoods recapitulating functional units of the tumor ecosystem and the spatial proximity of B and CD4+ T cells at immunogenic sites. Various organ-specific densities of tertiary lymphoid structures are observed. Immunosuppressive sites, including brain and liver metastases, are deposited with collagen I, and T cells at these sites highly express TIM-3. This study originally deciphers the single-cell landscape of the organ-specific TME at both cellular and spatial levels for LUAD, indicating the necessity for organ-specific treatment approaches.
Insights
Lung cancer immunotherapy response varies by organ. This study reveals distinct immune cell landscapes in primary tumors and metastases, guiding tailored treatment strategies.
Area of Science:
- Oncology
- Immunology
- Genomics
Background:
- Lung cancer exhibits heterogeneous organ-specific responses to immunotherapy.
- Understanding the tumor microenvironment (TME) is crucial for deciphering these divergent responses.
- Challenges in single-cell profiling of formalin-fixed paraffin-embedded (FFPE) materials hinder TME dissection.
Purpose of the Study:
- To dissect the organ-specific cellular and spatial TME in lung adenocarcinoma (LUAD) using FFPE samples.
- To reveal divergent immune niches and cellular neighborhoods across primary LUAD and its metastases.
- To identify mechanisms underlying differential immunotherapy responses in LUAD.
Main Methods:
- Single-cell nuclei RNA sequencing of 84,294 cells.
- Imaging mass cytometry (IMC) on 250,600 cells.
- Analysis of paired primary LUAD and metastatic FFPE samples.
Main Results:
- Divergent organ-specific immune niches were identified.
- Immunotherapy-responsive sites (primary LUAD, adrenal metastases) showed enrichment of B, plasma, and T cells.
- Immunosuppressive sites (brain, liver metastases) displayed collagen I deposition and T cells expressing TIM-3.
- Spatial proximity of B and CD4+ T cells was observed at immunogenic sites.
- Organ-specific densities of tertiary lymphoid structures were detected.
Conclusions:
- This study provides a comprehensive single-cell landscape of the organ-specific TME in LUAD at both cellular and spatial levels.
- Findings highlight the necessity for organ-specific treatment approaches in lung adenocarcinoma.
- The characterized TME features offer insights into immunotherapy resistance and response mechanisms.
More Related Videos
08:32Enrichment and Characterization of the Tumor Immune and Non-immune Microenvironments in Established Subcutaneous Murine Tumors
Published on: June 7, 2018
13:01Industrialized, Artificial Intelligence-guided Laser Microdissection for Microscaled Proteomic Analysis of the Tumor Microenvironment
Published on: June 3, 2022